Induction Therapy with Bortezomib-Cyclophosphamide-Dexamethasone (BCD) for Newly Diagnosed Transplant Eligible Patients with Multiple Myeloma

被引：0
|
作者：
Tsukada, Nobuhiro [1 ]
Ikeda, Masahiro [1 ]
Shingaki, Sumito [1 ]
Miyazaki, Kanji [1 ]
Meshitsuka, Sosuke [1 ]
Abe, Yu [1 ]
Yoshiki, Yumiko [1 ]
Suzuki, Kenshi [1 ]
机构：
[1] Japanese Red Cross Med Ctr, Div Hematol, Tokyo, Japan
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2015年 / 21卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2014.11.313
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
270
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [1] Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial
    Muranushi, Hiroyuki
    Kanda, Junya
    Kobayashi, Masayuki
    Maeda, Takeshi
    Kitano, Toshiyuki
    Tsuji, Masaaki
    Ueda, Yasunori
    Ishikawa, Takayuki
    Nohgawa, Masaharu
    Watanabe, Mitsumasa
    Imada, Kazunori
    Moriguchi, Toshinori
    Itoh, Mitsuru
    Ohno, Hitoshi
    Yonezawa, Akihito
    Hirata, Hirokazu
    Arima, Nobuyoshi
    Asagoe, Kohsuke
    Anzai, Naoyuki
    Nagata, Kayoko
    Yasuno, Shinji
    Kuwabara, Yoshihiro
    Kitao, Hiromi
    Kim, Ihhwa
    Kawagishi, Kiyomi
    Ueshima, Kenji
    Tominari, Shinjiro
    Nakayama, Takeo
    Yamashita, Kouhei
    Takaori-Kondo, Akifumi
    HEMATOLOGY, 2022, 27 (01) : 239 - 248
  • [2] BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE IS A GOOD INDUCTION TREATMENT FOR YOUNG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Lakhwani, S.
    Notario, C.
    de Bonis, C.
    Brena, J.
    Raya, J. M.
    Sanchez-Quintana, A.
    Rios-Rull, P.
    Trujillo-Gonzalez, M.
    Hernandez, M. T.
    HAEMATOLOGICA, 2014, 99 : 657 - 657
  • [3] A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
    Figueiredo, Amarilis
    Atkins, Harold
    Mallick, Ranjeeta
    Kekre, Natasha
    Kew, Andrea
    McCurdy, Arleigh
    BLOOD, 2016, 128 (22)
  • [4] BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE AS INDUCTION THERAPY FOR TRASPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS IN A SPANISH CENTRE
    Sole, M.
    Zapata, R.
    Palma, A.
    Ruiz, M. A.
    Rodriguez, J. N.
    Dominguez, J. F.
    Gomez, K.
    Ramirez, S.
    HAEMATOLOGICA, 2018, 103 : 28 - 28
  • [5] Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis
    Leiba, Merav
    Kedmi, Meirav
    Duek, Adrian
    Freidman, Tzachi
    Weiss, Mia
    Leiba, Ronit
    Nagler, Arnon
    Avigdor, Abraham
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (05) : 702 - 710
  • [6] Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) Compared to Bortezomib-Dexamethasone (Vel-Dex) As Induction Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
    Lavoie-Gagnon, Claudie
    St-Gelais, Jonathan
    Adam, Jean-Philippe
    Viens, Daniel
    Gagne, Felixe
    Decarie, Yann
    Lemieux-Blanchard, Emilie
    BLOOD, 2017, 130
  • [7] Bortezomib-lenalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation: A single center experience
    Kaloyannidis, P.
    Abduljalil, O.
    Abdulbaqi, M.
    Jatham, A.
    Estanislao, A.
    Raslan, H.
    Moinuddin, A.
    Apostolidis, J.
    Al Sagheir, A.
    Al Hashmi, H.
    Al Anazi, K.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S462 - S462
  • [8] Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma
    Figueiredo, A.
    Atkins, H.
    Mallick, R.
    Kekre, N.
    Kew, A.
    McCurdy, A.
    CURRENT ONCOLOGY, 2020, 27 (02) : E81 - E85
  • [9] Bortezomib-Cyclophosphamide-Dexamethasone for Relapsing Multiple Myeloma
    Fu, Weijun
    Delasalle, Kay
    Wang, Jialei
    Song, Shen
    Hou, Jian
    Alexanian, Raymond
    Wang, Michael
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (06): : 562 - 565
  • [10] Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to Bortezomib, Thalidomide and Dexamethasone (VTD) As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma
    Jimenez-Zepeda, Victor
    Bahlis, Nizar J.
    Duggan, Peter
    Alonso, Rafael
    Lahuerta, Juan Jose
    Valeri, Antonio
    Neri, Paola
    Tay, Jason
    Martinez-Lopez, Joaquin
    BLOOD, 2016, 128 (22)
12345